JP2005521685A5 - - Google Patents

Download PDF

Info

Publication number
JP2005521685A5
JP2005521685A5 JP2003567871A JP2003567871A JP2005521685A5 JP 2005521685 A5 JP2005521685 A5 JP 2005521685A5 JP 2003567871 A JP2003567871 A JP 2003567871A JP 2003567871 A JP2003567871 A JP 2003567871A JP 2005521685 A5 JP2005521685 A5 JP 2005521685A5
Authority
JP
Japan
Prior art keywords
calcium salt
phenylcarbamoyl
pyrrol
fluorophenyl
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003567871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005521685A (ja
Filing date
Publication date
Priority claimed from CZ20020413A external-priority patent/CZ296967B6/cs
Application filed filed Critical
Publication of JP2005521685A publication Critical patent/JP2005521685A/ja
Publication of JP2005521685A5 publication Critical patent/JP2005521685A5/ja
Pending legal-status Critical Current

Links

JP2003567871A 2002-02-01 2003-01-30 (3r,5r)7−[3−フェニル−4−フェニルカルバモイル−2−(4−フルオロフェニル)−5−イソプロピル−ピロール−1−イル]−3,5−ジヒドロキシヘプタン酸のヘミ−カルシウム塩(アトロバスタチン)の非晶質形を製造する方法 Pending JP2005521685A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20020413A CZ296967B6 (cs) 2002-02-01 2002-02-01 Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
PCT/CZ2003/000007 WO2003068739A1 (en) 2002-02-01 2003-01-30 Method of manufacturing an amorphous form of the hemi-calcium salt of (3r, 5r) 7- 3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (atorvastatin)

Publications (2)

Publication Number Publication Date
JP2005521685A JP2005521685A (ja) 2005-07-21
JP2005521685A5 true JP2005521685A5 (cg-RX-API-DMAC7.html) 2006-02-09

Family

ID=27674298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003567871A Pending JP2005521685A (ja) 2002-02-01 2003-01-30 (3r,5r)7−[3−フェニル−4−フェニルカルバモイル−2−(4−フルオロフェニル)−5−イソプロピル−ピロール−1−イル]−3,5−ジヒドロキシヘプタン酸のヘミ−カルシウム塩(アトロバスタチン)の非晶質形を製造する方法

Country Status (15)

Country Link
US (1) US7208608B2 (cg-RX-API-DMAC7.html)
EP (1) EP1470106B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005521685A (cg-RX-API-DMAC7.html)
KR (1) KR20040081172A (cg-RX-API-DMAC7.html)
AT (1) ATE480516T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003213986A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ296967B6 (cg-RX-API-DMAC7.html)
DE (1) DE60334068D1 (cg-RX-API-DMAC7.html)
EA (1) EA007432B1 (cg-RX-API-DMAC7.html)
ES (1) ES2347324T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0402590A3 (cg-RX-API-DMAC7.html)
PL (1) PL209756B1 (cg-RX-API-DMAC7.html)
PT (1) PT1470106E (cg-RX-API-DMAC7.html)
UA (1) UA76826C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003068739A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520740C (en) 2003-04-11 2012-06-05 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
WO2005005384A1 (en) * 2003-07-15 2005-01-20 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
CA2560252C (en) * 2004-03-17 2009-08-04 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
WO2006008091A2 (en) * 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
WO2006011155A1 (en) * 2004-07-26 2006-02-02 Apollo International Limited One pot process for amorphous atorvastain calcium
EP1784389A4 (en) * 2004-08-27 2009-03-25 Biocon Ltd PROCESS FOR THE PREPARATION OF AMORPHIC ATORVASTATIN CALCIUM
KR20090033405A (ko) * 2004-10-18 2009-04-02 테바 파마슈티컬 인더스트리즈 리미티드 알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에 아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를 제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는 방법
WO2006048893A2 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited A process for synthesis of large particle size statin compounds
CA2499047A1 (en) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
GB2424880A (en) * 2005-04-06 2006-10-11 Generics Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase
CA2619486C (en) 2005-08-15 2015-05-12 Arrow International Limited Crystalline and amorphous sodium atorvastatin
AU2006281237A1 (en) 2005-08-15 2007-02-22 Arrow International Limited Crystalline and amorphous sodium atorvastatin
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
WO2009139730A1 (en) * 2008-05-13 2009-11-19 Ulkar Kimya San. Ve Tic. A.S. Preparation of novel non-crystalline forms of atorvastatin calcium
KR101050722B1 (ko) * 2008-12-02 2011-07-21 대웅바이오 주식회사 무정형 아토르바스타틴 칼슘염의 제조방법
WO2010069593A1 (en) * 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en) * 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
CN103108863B (zh) * 2010-04-19 2015-08-19 中化帝斯曼制药有限公司荷兰公司 低醚杂质的阿托伐他汀的制备
CN108774164A (zh) * 2018-05-29 2018-11-09 宣城美诺华药业有限公司 一种阿托伐他汀钙合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
BR9609872A (pt) * 1995-07-17 1999-03-23 Warner Lambert Co Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino
PT848704E (pt) * 1995-07-17 2002-03-28 Warner Lambert Co Forma cristalina iii de um hemi-sal de calcio do acido ¬r-(r*,r*)|-2-(4-fluorofenil)-beta-delta-di-hidroxi-5-(1-metil-etil)-3-fenil-4-¬(fenilamino)carbonil|-1h-pirrole-1-heptanico(atorvastatina)
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
IN191236B (cg-RX-API-DMAC7.html) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
IN190564B (cg-RX-API-DMAC7.html) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
US7563911B2 (en) * 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)

Similar Documents

Publication Publication Date Title
US5385929A (en) [(Hydroxyphenylamino) carbonyl] pyrroles
DE69837681T2 (de) Verfahren zur herstellung von 1,3-diolen
EP1351963A1 (en) A process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds
MXPA03004276A (es) Hidrolisis de esteres del acido (r(r*, r*)-2 -(4-fluorofenil)- beta, delta- dihidroxi-5 -(1-metiletil)- 3-fenil-4 -((fenilamino) carbonil)- 1h-pirrol-1 -heptanoico con hidroxido de calcio.
JP2007137904A (ja) [R−(R*,R*)]−2−(4−フルオロフェニル)−β,δ−ジヒドロキシ−5−(1−メチルエチル)−3−フェニル−4−[(フェニルアミノ)カルボニル]−1H−ピロール−1−ヘプタン酸の塩又は錯体の製造法
US20050131055A1 (en) Method of manufacturing an amorphous form of the hemi-calcium salt of (3r, 5r) 7-3-phenly-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (actorvastatin)
US7812179B2 (en) Process for the preparation of atorvastatin and intermediates
US8188300B2 (en) Atorvastatin calcium propylene glycol solvates
WO2007099552A2 (en) Novel crystalline form of atovastatin hemi-magnesium
EP1704144A1 (en) A method of preparation of the hemi-calcium salt of (e)-7- [4-(4-fluorophenyl)-6-isopropyl-2- [me thyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxy-6-heptenoic acid
US7645888B2 (en) Process for the production of amorphous atorvastatin calcium
US7361772B2 (en) Process for the production of atorvastatin calcium
US7615647B2 (en) Process for producing atorvastatin hemicalcium
EP2075246A1 (en) A process for preparation of amorphous form of atorvastatin hemi-calcium salt
US20090099371A1 (en) Process for the preparation of amorphous atorvastatin calcium salt
WO2008053495A1 (en) A novel crystalline form of atorvastatin sodium
US20090221839A1 (en) Preparation of an Atorvastatin Intermediate
WO2006048888A1 (en) Novel process for the preparation of amorphous atorvastatin calcium salt
US20050165242A1 (en) Process for the preparation of amorphous atorvastatin calcium
WO2005033078A1 (en) Process for the production of atorvastatin calcium